REGULATORY

Govt to Erase Reference Pricing from Honebuto Policy, though Proposal Still Alive

June 8, 2017

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Japanese government will delete a proposal calling for the possible introduction of a reference pricing system for long-listed products (LLPs) from the text of its 2017 Basic Policy on Economic and Fiscal Management and Reform, dubbed honebuto, which is…

To read the full story

Japan Cabinet Adopts 2017 Honebuto Policy
June 12, 2017
Tweaking Likely for Honebuto Wording on Reference Pricing, Integration of Gx Price Bands
June 7, 2017
Draft Honebuto Policy OK’ed by CEFP, Says Distinguish “Me Too” Drugs from Pioneering Meds
June 5, 2017

REGULATORY

LDP Panel Finalizes Honebuto Proposal on Preventive Care, Adds Obesity Focus
June 5, 2026
Ex-GSK Japan Head Calls for End to "Obsolete" 14-Day Prescription Limit
June 5, 2026
Trazenta Generic Outlook Remains Clouded as Court Upholds Treatment-Method Patents
June 4, 2026
LDP Generic Caucus Wants Swift Disclosure of Company Indicator Ratings
June 4, 2026
LDP Social Security Panel Pushes Greater Reward for Innovation: Honebuto Proposal
June 3, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…